Detection of Blandm And Blaoxa-23 Genes in Acinetobacter Baumannii Isolated from Sputum Samples of Iraqi Patients

Authors

  • Luma Jasim Witwit Department of Microbiology, College of Dentistry, University of Babylon, Hilla, Iraq
  • Eman Jaber Raheem Al-Ardawi Ministry of Education, General Directorate of Education in Holy Karbala
  • Teeb Ahmed Altabtabaai Department of Field Crops, College of Agriculture, University of Al-Qasim Green, Babylon, Iraq

Keywords:

blaOXA-23, blaNDM, Acinetobacter baumannii, pneumonia, Carbapenemase

Abstract

Acinetobacter baumannii is a pivotal pathogenic bacterium causing hospital-acquired respiratory infections, particularly in critically ill patients, and its prevalence of multidrug-resistant strains has increased globally. Two of the most relevant carbapenemase genes from a clinical standpoint is blaOXA-23 and blaNDM which are highly involved in conferring resistance to carbapenems in A. baumannii. The aim of this study was to investigate the prevalence of the blaOXA-23 and blaNDM genes in A. baumannii isolates isolated from sputum samples obtained from Iraqi patients, and whether these genes were associated with patterns of resistance to specific antibiotics. This is a cross-sectional study performed in the Teaching Hospital in Al-Diwaniyah City, Iraq during March 2025 to August 2025. A total of 48 patients with a clinically suspected lower RTI were recruited. Sputum aspirates were obtained under aseptic conditions and processed by standard microbiological procedures. A. baumannii was identified by colony morphology, Gram staining and standard biochemical testing. The susceptibility testing for imipenem, meropenem, amikacin gentamicin ciprofloxacin ceftazidime and piperacillin–tazobactam (p-t) were performed by the Kirby–Bauer disk diffusion according to the CLSI. Molecular identification of blaOXA-23 and blaNDM genes was done by conventional polymerase chain reaction (PCR). High resistance rates were also noted for carbapenems, imipenem (87.5%) and meropenem (85.4%). Resistance was also high for ceftazidime (81.3%) and piperacillin/tazobactam (79.2%), which were much lower in case of aminoglycosides. Molecular investigation indicated that blaOXA-23 and blaNDM genes were observed in 83.3% and 37.5% of the isolates, respectively. The link between resistance to carbapenems and the simultaneous presence of blaOXA-23 and blaNDM genes was strongly significant. These observations show high rates of blaOXA-23 but still considerable rates of blaNDM enzymes among CRAB isolates in Al-Diwaniyah, and highlight the necessity for regular molecular surveillance, proper infection control measures and improved antimicrobial stewardship policies to prevent expansion of MDR A. baumannii strains.

References

Alkhawaja, A. A. K., & Hadi, Z. J. (2025). High Prevalence of blaNDM and blaOXA Carbapenemases in Multiple Antibiotic Resistant Acinetobacter baumannii from Iraqi Hospital. Kufa Medical Journal, 21(2), 30-41. https://doi.org/10.36330/kmj.v21.i2.19906

de Souza, J., D’Espindula, H. R. S., Ribeiro, I. d. F., Gonçalves, G. A., Pillonetto, M., & Faoro, H. (2025). Carbapenem Resistance in Acinetobacter baumannii: Mechanisms, Therapeutics, and Innovations. Microorganisms, 13(7), 1501. https://doi.org/10.3390/microorganisms13071501

Evans, B. A., & Amyes, S. G. (2014). OXA β-lactamases. Clinical microbiology reviews, 27(2), 241–263. https://doi.org/10.1128/CMR.00117-13

Kilbas, E. P. K., Kilbas, I., & Ciftci, I. H. (2023). Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii isolates in Turkiye: Systematic review. Northern clinics of Istanbul, 10(4), 531–539. https://doi.org/10.14744/nci.2022.17003

Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D. L., Rice, L. B., Stelling, J., Struelens, M. J., Vatopoulos, A., Weber, J. T., & Monnet, D. L. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(3), 268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x

Müller, C., Reuter, S., Wille, J., Xanthopoulou, K., Stefanik, D., Grundmann, H., Higgins, P. G., & Seifert, H. (2023). A global view on carbapenem-resistant Acinetobacter baumannii. mBio, 14(6), e0226023. https://doi.org/10.1128/mbio.02260-23

Odhafa, M. W., Al-Kadmy, I., Pourmand, M. R., Naderi, G., Asadian, M., Ghourchian, S., & Douraghi, M. (2024). The context of blaOXA-23 gene in Iraqi carbapenem-resistant Acinetobacter baumannii isolates belonging to global clone 1 and global clone 2. BMC research notes, 17(1), 300. https://doi.org/10.1186/s13104-024-06890-w

Papadopoulou, M., Deliolanis, I., Polemis, M., Vatopoulos, A., Psichogiou, M., & Giakkoupi, P. (2024). Characteristics of the Genetic Spread of Carbapenem-Resistant Acinetobacter baumannii in a Tertiary Greek Hospital. Genes, 15(4), 458. https://doi.org/10.3390/genes15040458

Poirel, L., Bonnin, R. A., & Nordmann, P. (2011). Genetic basis of antibiotic resistance in pathogenic Acinetobacter species. IUBMB life, 63(12), 1061–1067. https://doi.org/10.1002/iub.532

Rahbarnia, L., Farajnia, S., Khaneshi, H., Farajnia, H., Naghili, B., & Tanomand, A. (2020). Detection of blaOXA-23 and blaNDM-1 carbapenemase among clinical isolates of A. baumannii in Tabriz, north-west of Iran. Gene Reports, 18, 100555.

Ramoul, A., Loucif, L., Bakour, S., Amiri, S., Dekhil, M., & Rolain, J. M. (2016). Co-occurrence of blaNDM-1 with blaOXA-23 or blaOXA-58 in clinical multidrug-resistant Acinetobacter baumannii isolates in Algeria. Journal of global antimicrobial resistance, 6, 136–141. https://doi.org/10.1016/j.jgar.2016.05.003

Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., Ouellette, M., Outterson, K., Patel, J., Cavaleri, M., Cox, E. M., Houchens, C. R., Grayson, M. L., Hansen, P., Singh, N., Theuretzbacher, U., … WHO Pathogens Priority List Working Group (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet. Infectious diseases, 18(3), 318–327. https://doi.org/10.1016/S1473-3099(17)30753-3

Thacharodi, A., Vithlani, A., Hassan, S., Alqahtani, A., & Pugazhendhi, A. (2024). Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens. iScience, 27(12), 111367. https://doi.org/10.1016/j.isci.2024.111367

Wong, D., Nielsen, T. B., Bonomo, R. A., Pantapalangkoor, P., Luna, B., & Spellberg, B. (2017). Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clinical microbiology reviews, 30(1), 409–447. https://doi.org/10.1128/CMR.00058-16

Downloads

Published

2026-02-28